Trial Profile
Changes of cytokines and regulatory T cells in renal transplant recipients after switch to the mTOR inhibitor Everolimus. A Single center trial, non-blinded, non-randomized. [Veranderungen des Immunstatus bei nierentransplantierten Patienten nach Umstellung der immunsuppressiven Therapie auf den mTOR Inhibitor Everolimus. Eine nicht-verblindete, nicht-randomisierte, monozentrische Studie.]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Tacrolimus
- Indications Renal transplant rejection
- Focus Pharmacodynamics
- Acronyms Ever-cyto-Treg
- 11 Feb 2024 Status changed from recruiting to discontinued.
- 12 Apr 2013 New trial record